Charles Marcus
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Charles Marcus has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Mehdi Taghipour
From the *Russell H Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine; Departments of †Oncology, ‡Pathology, and §Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
2 shared publications- Rathan M. Subramaniam
University of Notre Dame, New Zealand
2 shared publications - Carole Fakhry
Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland
1 shared publication - Christian Sturesson
Division of Surgery and Oncology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital , Stockholm
1 shared publication Christophe M. Deroose
Nuclear Medicine, University Hospitals Leuven, Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium
1 shared publicationFabrizio Panaro
Department of Surgery, Division of HBP Surgery & Transplantation, Saint Eloi Hospital, Montpellier University Hospital, School of Medicine, 34000, Montpellier, France
1 shared publication
Latest Publications
- 29 May 2022
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 52 (6) , 662-672
18F-FDG PET/CT for Response Assessment in Lung Cancer
- 29 May 2022
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 52 (6) , 662-672
18F-FDG PET/CT for Response Assessment in Lung Cancer
- 1 February 2016
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 41 (2) , e93-e97
Follow-up FDG PET/CT in Patients With Non-Hodgkin Lymphoma
The aim of this study was to evaluate the value of each follow-up PET/CT in the clinical assessment of recurrence as well as determining its impact on management in patients with non-Hodgkin lymphoma (NHL). All patients diagnosed with NHL who had at least 1 follow-up PET/CT study, 6 months after primary treatment completion, were included. There were 204 eligible NHL patients with 560 follow-up PET/CT scans. The change in management was recorded after each follow-up PET/CT scan in comparison to the management plan before the study. Among the 560 scans, 388 scans (69.3%) were done without clinical suspicion and 172 scans (30.7%) were done with prior clinical suspicion of recurrence. Follow-up scan results suggested disease in 12.4% of the scans performed without clinical suspicion and ruled out disease in 16.3% scans performed with prior clinical suspicion. The management of NHL patients was changed after 37.8% of follow-up scans with prior clinical suspicion of recurrence and after 8.3% of scans in patients without prior clinical suspicion of recurrence. The management of NHL patients was not changed after 50.6% scans with prior clinical suspicion of recurrence of which 23.3% had no treatment before and after the scan and 27.3% had the same treatment continued before and after the scan. Follow-up FDG PET/CT performed with prior clinical suspicion of recurrence added value to patients with NHL for clinical assessment in 16.3% of the scan times and influenced the management in 37.8% of scan times. The management change was only 8.3% in patients without prior clinical suspicion of recurrence, and hence, surveillance FDG PET/CT in NHL should be avoided.
- 1 February 2016
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 41 (2) , e93-e97
Follow-up FDG PET/CT in Patients With Non-Hodgkin Lymphoma
The aim of this study was to evaluate the value of each follow-up PET/CT in the clinical assessment of recurrence as well as determining its impact on management in patients with non-Hodgkin lymphoma (NHL). All patients diagnosed with NHL who had at least 1 follow-up PET/CT study, 6 months after primary treatment completion, were included. There were 204 eligible NHL patients with 560 follow-up PET/CT scans. The change in management was recorded after each follow-up PET/CT scan in comparison to the management plan before the study. Among the 560 scans, 388 scans (69.3%) were done without clinical suspicion and 172 scans (30.7%) were done with prior clinical suspicion of recurrence. Follow-up scan results suggested disease in 12.4% of the scans performed without clinical suspicion and ruled out disease in 16.3% scans performed with prior clinical suspicion. The management of NHL patients was changed after 37.8% of follow-up scans with prior clinical suspicion of recurrence and after 8.3% of scans in patients without prior clinical suspicion of recurrence. The management of NHL patients was not changed after 50.6% scans with prior clinical suspicion of recurrence of which 23.3% had no treatment before and after the scan and 27.3% had the same treatment continued before and after the scan. Follow-up FDG PET/CT performed with prior clinical suspicion of recurrence added value to patients with NHL for clinical assessment in 16.3% of the scan times and influenced the management in 37.8% of scan times. The management change was only 8.3% in patients without prior clinical suspicion of recurrence, and hence, surveillance FDG PET/CT in NHL should be avoided.
- Open Access
- 7 September 2015
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 59 (6) , 681-686
The value of follow‐up FDG‐PET/CT in the management and prognosis of patients with HPV‐positive oropharyngeal squamous cell carcinoma
Introduction: To establish the accuracy of follow‐up fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT and the impact of FDG PET/CT result on management decisions and patient outcome prediction (overall and progression free survival) in human papilloma virus (HPV)‐positive oropharyngeal squamous cell carcinoma (SCC).Patients and Methods: We included 96 HPV‐positive oropharyngeal SCC (OPSCC) patients with 254 follow‐up PET/CT scans in the study. The PET/CT result accuracy was established with histopathology or 6‐month clinical follow‐up as reference standard. The impact on change in management was established for each follow‐up PET/CT scan. Overall survival was evaluated using Kaplan–Meier plots with a Log‐rank test.Results: The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of the follow‐up FDG‐PET/CT were 97.0%, 92.5%, 67.0%, 99.5% and 93.1%, respectively. Follow‐up PET/CT results were helpful in excluding tumour in 22% (9/41) of scans performed with prior clinical suspicion of disease and identified potential disease in 9.9% (21/213) scans performed without prior clinical suspicion. There was a change in management after 12.6% (32/254) scans. In 84.3% (214/254) scans, the patients were either observed or the same treatment was continued. The overall survival differed significantly between patients with a negative versus positive follow‐up scan (log rank P < 0.001). The median progression free survival was 28 months, if the first follow‐up scan performed within 6–12 months post‐treatment completion was negative.Conclusion: Follow‐up FDG PET/CT scans have an impact on the management plan and add value to clinical assessment in patients with HPV‐positive OPSCC.
- 7 September 2015
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 59 (6) , 681-686
Open AccessThe value of follow‐up FDG‐PET/CT in the management and prognosis of patients with HPV‐positive oropharyngeal squamous cell carcinoma
Introduction: To establish the accuracy of follow‐up fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT and the impact of FDG PET/CT result on management decisions and patient outcome prediction (overall and progression free survival) in human papilloma virus (HPV)‐positive oropharyngeal squamous cell carcinoma (SCC).Patients and Methods: We included 96 HPV‐positive oropharyngeal SCC (OPSCC) patients with 254 follow‐up PET/CT scans in the study. The PET/CT result accuracy was established with histopathology or 6‐month clinical follow‐up as reference standard. The impact on change in management was established for each follow‐up PET/CT scan. Overall survival was evaluated using Kaplan–Meier plots with a Log‐rank test.Results: The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of the follow‐up FDG‐PET/CT were 97.0%, 92.5%, 67.0%, 99.5% and 93.1%, respectively. Follow‐up PET/CT results were helpful in excluding tumour in 22% (9/41) of scans performed with prior clinical suspicion of disease and identified potential disease in 9.9% (21/213) scans performed without prior clinical suspicion. There was a change in management after 12.6% (32/254) scans. In 84.3% (214/254) scans, the patients were either observed or the same treatment was continued. The overall survival differed significantly between patients with a negative versus positive follow‐up scan (log rank P < 0.001). The median progression free survival was 28 months, if the first follow‐up scan performed within 6–12 months post‐treatment completion was negative.Conclusion: Follow‐up FDG PET/CT scans have an impact on the management plan and add value to clinical assessment in patients with HPV‐positive OPSCC.